Watch More Highlights

Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma, the optimal timing of novel agents as well as new agents showing promise, and combinations that may improve outcomes.

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.